Lantern Pharma Inc. (LTRN) intrinsic value & 10-year financials
Lantern Pharma Inc. (LTRN) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.67
- Market cap
- $7.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -168.6%
- Free cash flow (FY2025)
- -$15.7M
LTRN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$17.1M | -$1.57 | -$15.7M | — | -124.7% |
| FY2024 | — | -$20.8M | -$1.93 | -$17.8M | — | -126.9% |
| FY2023 | — | -$16.0M | -$1.47 | -$14.4M | — | -83.9% |
| FY2022 | — | -$14.3M | -$1.31 | -$12.8M | — | -70.9% |
| FY2021 | — | -$12.4M | — | -$10.6M | — | -61.5% |
| FY2020 | — | -$5.9M | — | — | — | -57.2% |
| FY2019 | — | -$2.4M | — | — | — | -655.0% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Lantern Pharma Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Lantern Pharma Inc. has historically struggled to out-earn its cost of capital, averaging just -76.0% ROIC.
Lantern Pharma Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Lantern Pharma Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.